Publicacións nas que colabora con Olalla Maroñas Amigo (35)

2025

  1. A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines

    International Journal of Molecular Sciences, Vol. 26, Núm. 17

  2. Balance of care activity after EMA recommendation for DPYD gene testing in Galicia

    Frontiers in Pharmacology, Vol. 16

  3. Differences in DPYD Population Frequencies Observed in Galicians Compared to Europeans and Spanish from PhotoDPYD Study

    Pharmaceuticals, Vol. 18, Núm. 4

  4. Exploring the sensory profile and pharmacogenetic biomarkers in child and youth ADHD patients undergoing methylphenidate (MPH) treatment: a systematic review conducted in European studies

    Journal of Psychiatric Research, Vol. 190, pp. 512-521

  5. Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrations

    Scientific Reports, Vol. 15, Núm. 1

  6. Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients

    Biomedicines, Vol. 13, Núm. 3

  7. The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review

    Pharmaceuticals, Vol. 18, Núm. 5

2024

  1. Farmacogenética

    Medicina interna (Elsevier España), pp. 1284-1291

  2. Role of CYP2D6 and CYP3A4 polymorphisms on aripiprazole and dehydroaripiprazole concentrations in patients undergoing long-acting treatment

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 135

  3. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. Deletion of the CYP2D6 gene as a likely explanation for the serious side effects of the antipsychotic drug pimozide: a case report

    Frontiers in Pharmacology, Vol. 14

2021

  1. Genetic diversity of drug-related genes in native americans of the brazilian amazon

    Pharmacogenomics and Personalized Medicine, Vol. 14, pp. 117-133

  2. Long runs of homozygosity are associated with Alzheimer’s disease

    Translational Psychiatry, Vol. 11, Núm. 1

  3. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics

    Pharmaceutics, Vol. 13, Núm. 7

2020

  1. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 8, pp. 1661-1666

  2. Anti-VEGF treatment and response in age-related macular degeneration: Disease’s susceptibility, pharmacogenetics and pharmacokinetics

    Current Medicinal Chemistry, Vol. 27, Núm. 4, pp. 549-569

  3. Association of BDNF, HTR2A, TPH1, SLC6A4, and comt polymorphisms with tdcs and escitalopram efficacy: Ancillary analysis of a double-blind, placebo-controlled trial

    Brazilian Journal of Psychiatry, Vol. 42, Núm. 2, pp. 128-135

  4. Farmacogenética

    Medicina interna [19ª ed.] (Elsevier España)

  5. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study

    Pharmacotherapy, Vol. 40, Núm. 1, pp. 17-25

  6. The road so far in colorectal cancer pharmacogenomics: Are we closer to individualised treatment?

    Journal of Personalized Medicine, Vol. 10, Núm. 4, pp. 1-40